Skip to main content
INCR
NASDAQ Life Sciences

InterCure receives Nasdaq delisting warning for minimum bid price non-compliance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.83
Mkt Cap
$45.391M
52W Low
$0.68
52W High
$1.77
52W Position info
22% above low
Off High info
53% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

INCR sits 22% above its 52-week low of $0.68 on light trading volume (0.1× avg).

Summary

InterCure Ltd. received a Nasdaq notification for failing to meet the minimum bid price requirement, initiating a 180-day period to regain compliance and potentially considering a reverse share split.


Key Events · Corporate Governance and Compliance · INCR

  • Nasdaq Minimum Bid Price Notification

    On February 25, 2026, InterCure Ltd. received a notice from Nasdaq indicating non-compliance with Listing Rule 5450(a)(2) because its ordinary shares traded below $1.00 for 30 consecutive business days.

  • 180-Day Compliance Period Granted

    The company has been granted a 180-calendar day period, until August 24, 2026, to regain compliance. To do so, the closing bid price must meet or exceed $1.00 per share for at least 10 consecutive business days.

  • Potential Reverse Share Split Considered

    InterCure intends to monitor its share price and is considering effecting a reverse share split, subject to corporate and regulatory approvals, as part of its plan to regain compliance.


Analysis · INCR · Life Sciences

InterCure Ltd. has received a formal notification from Nasdaq regarding its non-compliance with the minimum bid price requirement, as its stock has traded below $1.00 for 30 consecutive business days. This is a significant negative development as it signals potential delisting from the Nasdaq Global Market, which could severely impact the company's liquidity and investor confidence. While the company has a 180-day compliance period and plans to consider a reverse share split, this action is often viewed negatively by investors as it can be a cosmetic fix that doesn't address underlying business issues and can sometimes lead to further price erosion. Investors should monitor the company's progress in regaining compliance and the potential impact of any reverse share split.

At the time of this filing, INCR was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.4M. The 52-week trading range was $0.68 to $1.77. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INCR - Latest Insights

INCR
Jul 22, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.940
Real-time Price: $0.9247 info
Change: -$0.0153 (-2%) info
Market Cap: $54.461M info
INCR
Jun 22, 2026, 9:04 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.9689
Real-time Price: $0.9247 info
Change: -$0.0442 (-5%) info
Market Cap: $54.461M info
INCR
Jun 22, 2026, 8:50 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.9453
Real-time Price: $0.9247 info
Change: -$0.0206 (-2%) info
Market Cap: $54.461M info
INCR
Jun 15, 2026, 9:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.874
Real-time Price: $0.9247 info
Change: +$0.0507 (+6%) info
Market Cap: $54.461M info
INCR
Jun 15, 2026, 9:25 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.9151
Real-time Price: $0.9247 info
Change: +$0.0096 (+1%) info
Market Cap: $54.461M info